ABSTRACT

Background: An implantable loop recorder (ILR) is an effective tool for diagnosing unexplained syncope (US). We examined the diagnostic utility of an ILR in detecting arrhythmic causes of US and determining which clinical factors are associated with pacemaker (PM) implantation.

Methods: This retrospective, multicenter, observational study was conducted from February 2006 to April 2018 at 11 hospitals in Korea. Eligible patients with recurrent US received an ILR to diagnose recurrent syncope and document arrhythmia.

Results: A total of 173 US patients (mean age, 67.6 ± 16.5 years; 107 men [61.8%]) who received an ILR after a negative conventional workup were enrolled. During a mean follow-up of 9.4 ± 11.1 months, 52 patients (30.1%) had recurrent syncope, and syncope-correlated arrhythmia was confirmed in 34 patients (19.7%). The ILR analysis showed sinus node dysfunction in 24 patients (70.6%), supraventricular tachyarrhythmia in 4 (11.8%), ventricular arrhythmia in 4 (11.8%), and sudden atrioventricular block in 2 (5.9%). Overall, ILR detected significant arrhythmia in 99 patients (57.2%) irrespective of syncope. Among patients with clinically relevant arrhythmia detected by ILR, PM implantation was performed in 60 (34.7%), an intra-cardiac defibrillator in 5 (2.9%), and catheter ablation in 4 (2.3%).

Usefulness of an Implantable Loop Recorder in Diagnosing Unexplained Syncope and Predictors for Pacemaker Implantation

Sung Ho Lee, Tae-Hoon Kim, Yong-Seog Oh, Seil Oh, Jong-Il Choi, Jin-Bae Kim, Jong-Chun Nah, Sung Il Im, Ki-Woon Kang, Seongwook Han, and June Soo Kim
Role of ILR in Unexplained Syncope

INTRODUCTION

Syncope is a common problem in clinical practice. Although reflex syncope is frequently identified, approximately 30% of conventional diagnostic workups return a result of unexplained syncope (US). US can be a clinical manifestation of rare arrhythmia, and prolonged electrocardiogram (ECG) monitoring can detect intermittent or transient arrhythmia-related syncope if a symptom-correlated ECG is documented.

An implantable loop recorder (ILR) is an effective tool for detecting arrhythmia-related syncope. The European Society of Cardiology (ESC) guidelines recommend ILR in the early phases of evaluation for recurrent US. In pooled data from nine studies, 176 of 506 patients (35%) with US had a syncope-correlated ECG at the end of a complete workup; of these, 56% had asystole, 11% had tachycardia, and 33% had no arrhythmia. A significant asymptomatic arrhythmia, such as a prolonged pause (≥ 3 seconds) or supraventricular tachycardia (SVT) (i.e., > 160 beats/min for > 32 beats), and ventricular arrhythmia have been considered possible causes of US.

Previous ILR studies have shown that more than half of all cases of US are caused by asystole, and pacemaker (PM) implantation is highly effective in the case of syncope caused by brady-arrhythmia. Several studies have reported clinical predictors for later PM implantation in US patients.

We examined the usefulness of ILR-guided diagnosis of US (syncope-correlated arrhythmia, significant arrhythmia) and also analyzed the characteristics of patients likely to undergo PM implantation.

METHODS

Study population

Data for this multicenter, retrospective, observational study of 173 patients who received an ILR at 11 hospitals in Korea were gathered from February 2006 to April 2018. Enrolled patients with recurrent US and negative conventional diagnostic examinations received an ILR (Reveal Linq ICM, Reveal Plus, or Reveal Dx-XT; Medtronic Inc., Minneapolis, MN, USA or ConfirmTM; St. Jude Medical, St. Paul, MN, USA). The initial examinations for syncope evaluation included careful history-taking (total number and duration of syncope, prodromal symptoms, syncope-related injury, underlying disease), physical examination, baseline 12-lead ECG, two-dimensional echocardiography, 24-hour Holter, treadmill test, head-up tilt test (HUT), carotid sinus massage, and orthostatic blood pressure measurement. Invasive diagnostic tools, such as an electrophysiological study and coronary angiography were performed if clinically indicated.

A Cox regression analysis, history of paroxysmal atrial fibrillation (PAF) (hazard ratio [HR], 2.34; 95% confidence interval [CI], 1.33–4.12; P < 0.01) and any bundle branch block (BBB) (HR, 2.52; 95% CI, 1.09–5.85; P = 0.03) were significantly associated with PM implantation.

Conclusion: ILR is useful for detecting syncope-correlated arrhythmia in patients with US. The risk of PM is high in US patients with a history of PAF and any BBB.

Keywords: Implantable Loop Recorder; Unexplained Syncope; Pacemaker
When a neurologic cause was suspected, brain computed tomography or magnetic resonance imaging was performed. The conventional diagnostic tests performed for syncope evaluation before ILR implantation are shown in **Supplementary Table 1**.

Any hypertensive medication that could cause symptomatic bradycardia or hypotension, such as a beta-blocker or Ca blocker, was withheld before the conventional evaluation or ILR implantation at the physician’s discretion to determine whether they were causing the syncope. If the conventional examination did not reveal the cause of syncope, an ILR was implanted. Some physicians implanted an ILR when the clinical syncope was atypical for reflex syncope or orthostatic hypotension, even when the HUT or orthostatic BP measurement was positive.

Prodromal symptoms were defined as autonomic activation that occurred before unconsciousness, such as dizziness, nausea, vomiting, sweating, palpitation, or chest or abdominal discomfort. Major syncope-related injuries were defined as a major bone segment fracture, such as a skull fracture causing intracranial hemorrhage, and tooth subluxation. Minor syncope-related injuries were defined as swelling, ecchymosis or bruising, abrasion or laceration, and external superficial hematoma or minor bleeding.

Any bundle branch blocks (BBBs) were defined as left bundle branch block (LBBB) or right bundle branch block (RBBB) by a baseline 12-lead ECG, following the recent American Heart Association/American College of Cardiology/Heart Rhythm Society recommendations. Structural heart disease was defined as coronary artery disease (CAD), heart failure (HF), cardiomyopathy (CMP), or moderate to severe valvular heart disease (VHD).

**ILR implantation**

Each ILR was positioned subcutaneously in the left parasternal area at the level of the 4th–5th intercostal space under local anesthesia. The ILR stores rhythm strips when the patient presses a button in response to symptom occurrence (patient activation) or when the heart rate meets a preset limit (auto activation). The auto activation setting varied among patients, but it was generally programmed for a ventricular pause of > 3 seconds, a ventricular rate of < 40 beats/min, or a ventricular rate > 180 beats/min for more than 16 beats. Patients were taught to use the device prior to discharge after ILR implantation. Since small, insertable ILR devices (Reveal LINQTM ICM; Medtronic Inc., Minneapolis, MN, USA and Confirm RxTM; St. Jude Medical, St. Paul, MN, USA) came to the market in 2014 and 2017, respectively, ILR procedures have been simple and rapid and rarely entail major complications.

**Follow-up after ILR implantation**

Regular ILR follow-up at an outpatient clinic was performed at 3- to 6-month intervals at the physician’s discretion. Immediate ILR interrogation was performed in the case of recurrent syncope. The ILR remained implanted until a diagnostic event was recorded or until the end of the battery life. If no diagnosis of syncope was made before the end of the battery life, removal or reinsertion of the ILR was performed at the physician’s discretion.

**Study endpoint**

The primary endpoint was a symptom-correlated ECG diagnosis by ILR interrogation during the first recurrent syncope after implantation of the ILR. The secondary endpoint was significant arrhythmia irrespective of syncope, defined as a ventricular pause of > 3 seconds, a ventricular rate of < 40 beats/min, or a ventricular rate > 180 beats/min for more than 16 beats.
Statistical analysis
Continuous variables are expressed as the mean ± standard deviation. A χ² analysis was used for categorical data, independent t-tests for continuous data, and Mann-Whitney tests for nonparametric cases. Cumulative incidence and event-free curves were derived using Kaplan-Meier analyses, stratified by study groups, and compared using the log-rank test. To identify independent predictors for PM implantation, we first conducted univariate analyses and then included predictors with a significance level < 10% in a multivariable Cox proportional hazards model with a 95% confidence interval (CI). All P-values were two-sided, and statistical significance was accepted at P < 0.05. Data were analyzed using Statistical Package for the Social Sciences, version 11.0 (SPSS, Inc., Chicago, IL, USA) with Windows 2000 (Microsoft, Redmond, WA, USA).

Ethics statement
This study was approved by each Institutional Review Board (IRB) (Samsung Medical Center, IRB No. 2017-12-120). The requirement for informed consent was waived because we used only anonymized retrospective data that were routinely collected during clinical practice.

RESULTS

Patient characteristics
The study population is summarized in Fig. 1 and baseline characteristics of the study population are shown in Table 1. A total of 173 recurrent US patients (mean age, 67.6 ± 16.5 years; 62% men) were analyzed. The median number of previous cases of syncope was 3 (interquartile range, 2–5). Hypertension was present in 89 patients (51.4%), and a history of paroxysmal atrial fibrillation (AF) was noted in 41 (24%). Structural heart disease was present in 30 patients (17.3%): CMP in 13 (7.5%), CAD in 9 (5.2%), HF in 5 (2.9%), and VHD in 3 (1.7%). Significant CAD was re-vascularized. The VHD patients were 2 cases with moderate aortic valve stenosis and 1 with a well-functioning prosthetic valve. Those conditions were not directly associated with syncope.

Fig. 1. Flow chart of study population.
ILR = implantable loop recorder, ECG = electrocardiogram.
First syncope recurrences after ILR implantation

Symptom-correlated arrhythmia and ILR-guided therapy are shown in Table 2. A total of 52 patients (30.1%) experienced a first recurrence of syncope after ILR implantation during the mean follow-up period of 9.1 ± 13.7 months. The cumulative incidence of recurrent syncope was 34.3% and 47.2% at 1 and 2 years, respectively (Fig. 2A). Among those patients, a symptom-correlated ECG diagnosis during syncope was made by the ILR in 34 (65.3%) cases. Bradycardia related arrhythmia diagnoses were as follows: 24 sinus node dysfunction and 2 sudden atrioventricular (AV) blocks. Tachy-arrhythmia syncope diagnoses were as follows: 4 SVT, 2 ventricular tachycardia (VT), and 2 ventricular fibrillation (VF). As ILR-guided therapy, 25 (73.5%) patients underwent PM implantation, and 3 patients underwent implantable cardioverter defibrillator (ICD) implantation.

Significant arrhythmia documented by ILR interrogation irrespective of syncope

Significant arrhythmia documented by IRL irrespective of syncope and the corresponding ILR-guided therapies are shown in Supplementary Table 2. Significant arrhythmia was

---

**Table 1. Baseline characteristics of the study population**

| Variables                        | Values (n = 173) |
|----------------------------------|------------------|
| Gender, men                      | 107 (61.8)       |
| Age, yr                          | 67.6 ± 16.5      |
| BMI, kg/m²                       | 24.4 ± 3.2       |
| Previous number of syncope       | 3 (2–5)          |
| History of syncope in the previous 2 years | 2 (1–4) |
| Syncope duration, yr             | 1 (0.1–3)        |

**Underlying disease**

- Hypertension: 89 (51.4)
- Diabetes: 41 (23.7)
- Cardiomyopathy: 13 (7.5)
- HCMP: 8 (4.6)
- DCMP: 3 (1.7)
- ICMP: 2 (1.2)
- Coronary artery disease: 9 (5.2)
- Congestive heart failure: 5 (2.9)
- Valvular heart disease: 3 (1.7)
- Moderate AS: 2 (0.1)
- Prosthetic aortic valve and mitral valve: 1 (0.5)

**AF history**

- Paroxysmal AF: 41 (23.7)
- Persistent AF: 4 (2.3)

**Antihypertensive medication**

- Beta blocker: 46 (26.6)
- Ca blocker: 25 (14.5)
- Diuretics: 17 (9.8)
- ACE inhibitor: 17 (9.8)

**Syncope-related minor injury**

- 38 (22.0)

**Syncope-related major injury**

- 12 (6.9)

**Prodromal symptoms**

- 83 (48.0)
- Dizziness: 62 (35.8)
- Chest discomfort: 22 (12.7)
- Palpitation: 17 (9.8)
- Blurred vision: 13 (7.5)
- Nausea: 11 (6.4)
- Diaphoresis: 10 (5.8)
- Abdominal pain: 4 (2.3)
- Dyspnea: 1 (0.6)

Data are presented as number (median), or mean ± standard deviation, and number (%).

BMI = body mass index, HCMP = hypertrophic cardiomyopathy, DCMP = dilated cardiomyopathy, ICMP = ischemic cardiomyopathy, AS = aortic valve stenosis, AF = atrial fibrillation, ACE = Angiotensin-converting enzyme.
documented by ILR irrespective of syncope in 99 (57.2%) patients after the mean follow-up of 5.5 ± 7.9 months. The cumulative incidence of ILR-guided therapy was 47.8% and 57.1% at 1 and 2 years, respectively. (Fig. 2B). A device (PM or ICD) was implanted if the significant arrhythmia found by ILR interrogation was deemed a possible cause of the clinical syncope by the physician, following the ESC guidelines.24 A PM was implanted in 60 patients (34.7%), 5 (2.9%) received an ICD, and 4 (2.3%) underwent radiofrequency catheter ablation (RFCA).

### Subgroup analysis between PM groups

A total of 60 patients (34.7%) underwent PM implantation during a mean follow-up period of 6.0 ± 9.3 months. Comparisons between patients who received a PM and those who did not are shown in Table 3. The PM group was older, took more antihypertensive medication, had a higher proportion of paroxysmal AF history and relatively short duration of syncope, and were more likely to have had any BBB on the baseline 12-lead ECG. The univariable analyses

### Table 2. Documented arrhythmia during first syncope and ILR-guided therapy

| Documented arrhythmia                        | Values (n = 34) | ILR-guided therapy |
|---------------------------------------------|----------------|--------------------|
| Sinus node dysfunction                      | 24 (70.6)      |                    |
| Sinus pause                                 |                |                    |
| Sinus pause (> 3 sec, < 6 sec)              | 6 (17.6)       | PPM (66.7)         |
| Sinus pause (> 6 sec)                       | 12 (35.3)      | PPM (100)          |
| Bradycardia                                 |                |                    |
| Sinus bradycardia                           | 4 (11.8)       | PPM (100)          |
| AF with slow ventricular response           | 2 (5.9)        | PPM (100)          |
| AV block                                    | 2 (5.9)        | PPM (100)          |
| Supraventricular tachyarrhythmias          | 4 (11.8)       |                    |
| SVT                                         | 1 (2.9)        |                    |
| AF with rapid ventricular response          | 3 (8.8)        |                    |
| Ventricular tachyarrhythmias                | 4 (11.8)       |                    |
| Ventricular tachycardia                     | 2 (5.9)        | ICD (50)           |
| Ventricular fibrillation                     | 2 (5.9)        | RFCA (50)          |

Data are presented as number (%). ILR = implantable loop recorder, PPM = permanent pacemaker, AF = atrial fibrillation, AV = atrioventricular, SVT = supraventricular tachycardia, ICD = implantable cardioverter defibrillator, RFCA = radiofrequency catheter ablation.

Fig. 2. Cumulative incidence of recurrent syncope and ILR-guided therapy. (A) Cumulative incidence of recurrent syncope. (B) Cumulative incidence of ILR-guided therapy. ILR = implantable loop recorder.
showed that age > 75 years (hazard ratio [HR], 1.97; 95% CI, 1.18–3.30; \( P < 0.01 \)), a history of paroxysmal AF (HR, 2.73; 95% CI, 1.62–4.58; \( P < 0.01 \)), and any BBB on the baseline 12-lead ECG (HR, 2.98; 95% CI, 1.35–6.58; \( P < 0.01 \)) were significantly associated with later PM implantation (Fig. 3). The multivariable analysis showed that a history of paroxysmal AF (HR, 2.34; 95% CI, 1.33–4.12; \( P = 0.01 \)) and any BBB on the baseline 12-lead ECG (HR, 2.52, 95% CI, 1.09–5.85; \( P = 0.03 \)) were significantly associated with PM implantation (Table 4).

### Table 3. Clinical characteristics of patients receiving pacemaker implantation

| Variables                              | Not receiving pacemaker (n = 113) | Receiving pacemaker (n = 60) | \( P \) value |
|----------------------------------------|-----------------------------------|-------------------------------|--------------|
| Gender, men                            | 69 (61.3)                         | 38 (63.3)                     | 0.77         |
| Age, yr                                | 64.2 ± 17.3                       | 74.5 ± 12.3                   | < 0.01       |
| BMI, kg/m²                              | 24.5 ± 3.3                        | 24.2 ± 2.9                    | 0.24         |
| Previous number of syncope             | 3 (2–4)                           | 3 (2–5)                       | 0.94         |
| History of syncope in previous 2 years | 2 (1–3)                           | 3 (2–4)                       | 0.42         |
| Syncope duration, yr                   | 3.7 ± 6.7                         | 1.9 ± 3.8                     | 0.07         |
| Underlying disease                     |                                   |                               |              |
| Hypertension                           | 52 (47.3)                         | 37 (61.7)                     | 0.07         |
| Diabetes                               | 23 (20.4)                         | 19 (31.7)                     | 0.11         |
| Congestive heart failure               | 3 (2.7)                           | 2 (3.3)                       | 0.80         |
| Coronary artery disease                | 28 (24.8)                         | 19 (31.7)                     | 0.33         |
| Cardiomyopathy                         | 9 (8.0)                           | 4 (6.7)                       | 0.75         |
| Valvular heart disease                 | 1 (0.9)                           | 2 (3.3)                       | 0.28         |
| AF history                             | 19 (17.4)                         | 26 (42.3)                     | 0.01         |
| Paroxysmal AF                          | 17 (15.6)                         | 24 (40.0)                     |              |
| Persistent AF                          | 2 (1.8)                           | 2 (3.3)                       |              |
| Antihypertensive medication            | 41 (37.3)                         | 26 (44.1)                     | 0.38         |
| Beta blocker                           | 30 (27.8)                         | 15 (25.0)                     | 0.69         |
| Diuretics                              | 11 (10.1)                         | 6 (10.0)                      | 0.98         |
| ACE inhibitor                          | 10 (9.2)                          | 7 (11.7)                      | 0.60         |
| Ca blocker                             | 19 (17.3)                         | 6 (10.0)                      | 0.24         |
| Sinus bradycardia                      | 7 (6.2)                           | 5 (8.3)                       | 0.75         |
| First AV block                         | 5 (8.3)                           |                               |              |
| PVC                                    | 6 (5.3)                           | 8 (13.3)                      | 0.08         |
| AF                                     | 4 (3.5)                           | 0                               | 0.29         |
| PVC                                    | 5 (4.4)                           | 7 (11.7)                      | 0.11         |
| IVCD                                   | 0                                 | 1 (1.7)                       | 0.34         |
| Any branch block                       | 3 (2.7)                           | 7 (11.7)                      | 0.03         |
| RBBB                                   | 2 (1.8)                           | 4 (6.7)                       | 0.18         |
| LBBB                                   | 0                                 | 2 (3.3)                       | 0.11         |
| Bifascicular block (RBBB, LAFB)        | 1 (0.9)                           | 1 (1.7)                       | 0.99         |

Data are presented as number (median), or mean ± standard deviation, and number (%).

BMI = body mass index, AF = atrial fibrillation, ACE = angiotensin-converting enzyme, ECG = electrocardiogram, AV = atrioventricular, PVC = premature ventricular complex, IVCD = intraventricular conduction block, RBBB = right bundle branch block, LBBB = left bundle branch block, LAFB = left anterior fascicular block.

---

### Table 4. Clinical predictors of pacemaker implantation in patients with implantable loop recorder

| Variables                              | Univariable analysis | Multivariable analysis |
|----------------------------------------|----------------------|------------------------|
|                                        | HR                   | 95% CI                 | \( P \) value | HR                   | 95% CI                 | \( P \) value |
| Age, > 75 yr                           | 1.97                 | 1.18–3.30              | < 0.01       | 1.33                 | 0.74–2.37              | 0.33         |
| Paroxysmal AF history                  | 2.73                 | 1.62–4.58              | < 0.01       | 2.34                 | 1.33–4.12              | < 0.01       |
| Hypertension                           | 1.58                 | 0.94–2.67              | 0.08         | 1.21                 | 0.70–2.01              | 0.48         |
| Any bundle branch block                | 2.98                 | 1.35–6.58              | < 0.01       | 2.52                 | 1.09–5.85              | 0.03         |
| First AV block at ECG                  | 1.71                 | 0.81–3.69              | 0.15         |                     |                       |              |
| Duration of syncope                    | 0.92                 | 0.84–1.02              | 0.13         |                     |                       |              |

HR = hazard ratio, CI = confidence interval, AF = atrial fibrillation, AV = atrioventricular, ECG = electrocardiogram.
The main finding of our study is that ILR for US diagnosis detected recurrent syncope in 52 patients (30%), symptom-correlated ECG in 34 (19.6%), and significant arrhythmia irrespective of syncope in 99 (57.2%). A total of 69 (39.8%) patients were effectively treated with a PM, ICD, or RFCA as a result of ILR-guided diagnosis. These results are comparable to those of previous studies.\textsuperscript{15,23,25,26} Elderly US patients with a history of paroxysmal AF or any BBB on the baseline ECG could have a higher risk of later PM implantation. To our knowledge, this is the first study to evaluate the utility of ILR and clinical predictors of PM implantation in a large number of Asian patients.

The detection rate for significant arrhythmia irrespective of syncope was 57%, which is also comparable with a previous study\textsuperscript{25} that reported that 60% of ILR patients were diagnosed as having had an arrhythmic event. Significant arrhythmia regardless of syncope was diagnosed more frequently than syncope-related ECG. Krahn et al.\textsuperscript{15} reported that pre-specified significant asymptomatic arrhythmia was automatically detected by the ILR in 9 US patients (15%), with 7 of those patients later undergoing PM implantation. We did not classify the

\textbf{DISCUSSION}

Fig. 3. Cumulative incidence of pacemaker implantation by risk factors. (A) Cumulative incidence of pacemaker implantation by older age (≥ 75 years). (B) Cumulative incidence of pacemaker implantation by history of paroxysmal AF. (C) Cumulative incidence of pacemaker implantation by any bundle branch block. ILR = implantable loop recorder, PAF = paroxysmal atrial fibrillation, AF = atrial fibrillation.

| Months | No. at risk | Age < 75 | Age ≥ 75 |
|--------|-------------|----------|----------|
| 0      | 107         | 18       | 11       |
| 10     | 35          | 11       | 6        |
| 20     | 20          | 6        | 4        |
| 30     | 5           | 2        | 0        |
| 40     | 2           | 0        |          |

| Months | No. at risk | No PAF history | PAF history |
|--------|-------------|----------------|-------------|
| 0      | 132         | 41             | 84          |
| 10     | 45          | 8              | 37          |
| 20     | 27          | 4              | 23          |
| 30     | 9           | 2              | 7           |
| 40     | 4           | 2              | 2           |
| 50     | 1           | 0              | 1           |

| Months | No. at risk | No any bundle branch block | Any bundle branch block |
|--------|-------------|---------------------------|------------------------|
| 0      | 163         | 10                         | 163                    |
| 10     | 51          | 2                          | 49                     |
| 20     | 30          | 1                          | 29                     |
| 30     | 11          | 0                          | 11                     |
| 40     | 6           | 0                          | 6                      |
| 50     | 1           | 0                          | 1                      |
pre-specified significant vs. borderline asymptomatic arrhythmia as they did; we speculated that physicians might implant a PM under the assumption that a pre-specified significant arrhythmia is likely to cause syncope.²⁴

Some previous studies have reported finding symptom-correlated ECG in 36%–64% of US patients, depending on the study population and incidence of structural heart disease,¹³,²⁵,²⁶ which is known to be an important predictor of cardiac syncope.²⁷ Although previous studies differ in their reporting, structural heart disease is present in 33%–48% of US patients.²⁵,²⁶,²⁸ In our study, the ILR established a symptom-correlated ECG in 19.6% (34/173) of the whole study population, which is lower than reported in other studies,²⁵,²⁶ possibly because our study population included fewer patients with structural heart disease than previous studies and our follow-up period was relatively short.

The PM subgroup analysis showed that age > 75 years, a history of paroxysmal AF, and any BBB on the baseline 12-lead ECG were also associated with PM implantation. Several previous studies reported clinical predictors for PM implantation in US patients.¹⁹-²¹,²⁶ Old age is the most common predictor, as expected.¹⁹,²⁰,²⁶ Intermittent sinus node dysfunction (SND) from degenerative fibrosis or a paroxysmal AV block with aging are associated with US.²⁹,³⁰ SND at an older age could manifest as tachycardia-bradycardia syndrome or AF with slow ventricular response (SVR).³¹,³² In 40% to 70% patients, AF is present at the time of initial diagnosis with SND.³³,³⁴ Brignole et al.⁹ reported that a paroxysmal AV block was a frequent cause of syncope in recurrent syncope patients with a BBB and a negative electrophysiological test, suggesting that BBB carry a high risk of pathological conduction-system abnormalities. In our study population, 70% (7/10) of patients with any BBB received a PM. If we initially evaluated US patients with a history of paroxysmal AF or any BBB on the baseline ECG, arrhythmic cause might be more likely than reflex syncope.

Our study has several limitations. First, we could not accurately classify the PM-indicated group because a detailed clinical history of syncope and meticulous ILR electrocardiogram data were not acquired in every hospital. If all patients with significant arrhythmia were classified as the PM-indicated group, it could have biased the results because that group might have included patients with bradycardia from reflex syncope or those with asymptomatic bradycardia. Second, sinus bradycardia in young patients, increased vagal tone during sleep or pain, or reflex syncope might not be distinguishable from SND. Some paroxysmal AV blocks can occur in association with increased vagal tone. Although each physician carefully evaluated clinical histories, we cannot exclude the possibility that a reflex mechanism was responsible for the arrhythmia. Third, a fine F wave in AF with SVR and a small P wave with a paroxysmal AV block could not be differentiated by ILR interrogation because of the low amplitude of the ILR-detected P waves or undersensing of the P wave. Fourth, because the sensing value of R or P waves was not acquired at every hospital, false bradycardia from undersensing and false tachycardia from oversensing caused by artifacts or poor R-wave sensing are possible. Fifth, the number of patients with any BBB (RBBB, LBBB, or a bi-fascicular block) is relatively small. Lastly, a longer follow-up period might have revealed further syncope-related ECG among patients with significant arrhythmia.

In conclusion, the diagnostic utility of ILR for detecting symptom-correlated ECG and significant arrhythmia in a large number of Asian US patients was comparable to previous
Western results. Bradycardia was the most common etiology of US. US patients with a history of paroxysmal AF or any BBB on the baseline ECG were at higher risk of PM implantation.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Conventional diagnostic tests for syncope evaluation before implantable loop recorder implantation

Click here to view

Supplementary Table 2
Significant arrhythmia documented by ILR and ILR-guided therapy

Click here to view

REFERENCES

1. Chen L, Chen MH, Larson MG, Evans J, Benjamin EJ, Levy D. Risk factors for syncope in a community-based sample (the Framingham Heart Study). Am J Cardiol 2000;85(10):1189-93.
2. Krahn AD, Klein GJ, Yee R, Takle-Newhouse T, Norris C; Reveal Investigators. Use of an extended monitoring strategy in patients with problematic syncope. Circulation 1999;99(3):406-10.
3. Soteriades ES, Evans JC, Larson MG, Chen MH, Chen L, Benjamin EJ, et al. Incidence and prognosis of syncope. N Engl J Med 2002;347(12):878-85.
4. Farwell DJ, Freemantle N, Sulke N. The clinical impact of implantable loop recorders in patients with syncope. Eur Heart J 2006;27(3):351-6.
5. Krahn AD, Klein GJ, Yee R, Skanes AC. Randomized assessment of syncope trial: conventional diagnostic testing versus a prolonged monitoring strategy. Circulation 2001;104(1):46-51.
6. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39(21):1883-948.
7. Moya A, Brignole M, Menozzi C, Garcia-Civera R, Tognarini S, Mont L, et al. Mechanism of syncope in patients with isolated syncope and in patients with tilt-positive syncope. Circulation 2001;104(11):1261-7.
8. Menozzi C, Brignole M, Garcia-Civera R, Moya A, Botto G, Tercedor L, et al. Mechanism of syncope in patients with heart disease and negative electrophysiologic test. Circulation 2002;105(23):2741-5.
9. Brignole M, Menozzi C, Moya A, Garcia-Civera R, Mont L, Alvarez M, et al. Mechanism of syncope in patients with bundle branch block and negative electrophysiological test. Circulation 2001;104(17):2045-50.
10. Krahn AD, Klein GJ, Norris C, Yee R. The etiology of syncope in patients with negative tilt table and electrophysiologic testing. Circulation 1995;92(7):1819-24.
11. Nierop PR, van Mechelen R, van Elsäcker A, Luijten RH, Elhendy A. Heart rhythm during syncope and presyncope: results of implantable loop recorders. Pacing Clin Electrophysiol 2000;23(10 Pt 1):1532-8.
12. Boersma L, Mont L, Sionis A, García E, Brugada J. Value of the implantable loop recorder for the management of patients with unexplained syncope. Europace 2004;6(1):70-6.
13. Lombardi F, Calosso E, Mascioli G, Marangoni E, Donato A, Rossi S, et al. Utility of implantable loop recorder (Reveal Plus) in the diagnosis of unexplained syncope. *Europace* 2005;7(1):19-24.

14. Pierre B, Fauchier L, Bread G, Marie O, Poret P, Babuty D. Implantable loop recorder for recurrent syncope: influence of cardiac conduction abnormalities showing up on resting electrocardiogram and of underlying cardiac disease on follow-up developments. *Europace* 2008;10(4):477-81.

15. Krahn AD, Klein GI, Yee R, Skanes AC. Detection of asymptomatic arrhythmias in unexplained syncope. *Am Heart J* 2004;148(2):326-32.

16. Moya A, García-Civera R, Croci F, Menozzi C, Brugada J, Ammirati F, et al. Diagnosis, management, and outcomes of patients with syncope and bundle branch block. *Eur Heart J* 2011;32(12):1535-41.

17. Brignole M, Vardas P, Hoffman E, Huikuri H, Moya A, Ricci R, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. *Europace* 2009;11(5):671-87.

18. Lacunza-Ruiz FJ, Moya-Mitjans A, Martinez-Alday J, Barón-Esquivias G, Ruiz-Granell R, Rivas-Gándara N, et al. Implantable loop recorder allows an etiologic diagnosis in one-third of patients. Results of the Spanish reveal registry. *Circ J* 2013;77(10):2535-41.

19. Palmisano P, Accogli M, Zaccaria M, Luzzi G, Nacci F, Anaclerio M, et al. Predictive factors for pacemaker implantation in patients receiving an implantable loop recorder for syncope remained unexplained after an extensive cardiac and neurological workup. *Int J Cardiol* 2013;168(4):3450-7.

20. Magnunsson PM, Olszowa M, Wallhagen M, Koyi H. Outcome of implantable loop recorder evaluation. *Cardiol J* 2018;25(3):363-70.

21. Huemer M, Becker AK, Wutzler A, Attanasio P, Parwani AS, Lacour P, et al. Implantable loop recorders in patients with unexplained syncope: Clinical predictors of pacemaker implantation. *Cardiol J* 2019;26(1):36-46.

22. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. *J Am Coll Cardiol* 2009;53(11):992-1002.

23. Maines M, Zorzi A, Tomasi G, Angeheben C, Catanzariti D, Piffer L, et al. Clinical impact, safety, and accuracy of the remotely monitored implantable loop recorder Medtronic Reveal LINQTM. *Europace* 2018;20(6):1050-7.

24. Entem FR, Enriquez SG, Cobo M, Expósito V, Llano M, Ruiz M, et al. Utility of implantable loop recorders for diagnosing unexplained syncope in clinical practice. *Clin Cardiol* 2009;32(1):28-31.

25. Krahn AD, Klein GI, Fitzpatrick A, Seidl K, Zaidi A, Skanes A, et al. Predicting the outcome of patients with unexplained syncope undergoing prolonged monitoring. *Pacing Clin Electrophysiol* 2002;25(1):37-41.

26. Alboni P, Brignole M, Menozzi C, Raviele A, Del Rosso A, Dinelli M, et al. Diagnostic value of history in patients with syncope with or without heart disease. *J Am Coll Cardiol* 2001;37(7):1921-8.

27. Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. *Eur Heart J* 2004;25(14):1257-63.

28. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SI, Vohra IK, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. *J Am Coll Cardiol* 2004;44(1):109-16.
30. Akoum N, McGann C, Vergara G, Badger T, Ranjan R, Mahnkopf C, et al. Atrial fibrosis quantified using late gadolinium enhancement MRI is associated with sinus node dysfunction requiring pacemaker implant. *J Cardiovasc Electrophysiol* 2012;23(1):44-50.

31. Hadian D, Zipes DP, Olgin JE, Miller JM. Short-term rapid atrial pacing produces electrical remodeling of sinus node function in humans. *J Cardiovasc Electrophysiol* 2002;13(6):584-6.

32. John RM, Kumar S. Sinus node and atrial arrhythmias. *Circulation* 2016;133(19):1892-900.

33. Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. *J Cardiovasc Electrophysiol* 2002;13(6):542-7.

34. Alonso A, Jensen PN, Lopez FL, Chen LY, Psaty BM, Folsom AR, et al. Association of sick sinus syndrome with incident cardiovascular disease and mortality: the Atherosclerosis Risk in Communities study and Cardiovascular Health Study. *PLoS One* 2014;9(10):e109662.